Cohort | Time (Years) | ||||||
---|---|---|---|---|---|---|---|
0.5 | 1 | 2 | 3 | 4 | 5 | ||
A) Elevated-TG analysis | |||||||
Study population with baseline CHF (1) | Proportion | 0.6407 | 0.4965 | 0.3838 | 0.2977 | 0.2467 | 0.2170 |
At risk | 781 | 498 | 297 | 185 | 109 | 78 | |
Study population with no baseline CHF (2) | Proportion | 0.6030 | 0.4697 | 0.3364 | 0.2664 | 0.2194 | 0.1865 |
At risk | 13,178 | 8774 | 4966 | 3263 | 1925 | 1293 | |
Comparison group with baseline CHF (3) | Proportion | 0.6286 | 0.4885 | 0.3642 | 0.2925 | 0.2474 | 0.2119 |
At risk | 667 | 435 | 248 | 160 | 92 | 64 | |
Comparison group with no | Proportion | 0.5966 | 0.4714 | 0.3432 | 0.2742 | 0.2257 | 0.1927 |
baseline CHF (4) | At risk | 13,129 | 8961 | 5166 | 3477 | 2026 | 1371 |
Clustered P values for between-group comparisons in the elevated-TG analysis | |||||||
1 vs 2 | 1 vs 3 | 1 vs 4 | 2 vs 3 | 2 vs 4 | 3 vs 4 | ||
0.010 | 0.777 | 0.019 | 0.045 | 0.426 | 0.071 | ||
B) High-TG analysis | |||||||
Study population with baseline CHF (1) | Proportion | 0.6275 | 0.4813 | 0.3888 | 0.3019 | 0.2440 | 0.2235 |
At risk | 378 | 235 | 147 | 89 | 50 | 39 | |
Study population with no baseline CHF (2) | Proportion | 0.5888 | 0.4550 | 0.3200 | 0.2517 | 0.2021 | 0.1711 |
At risk | 6087 | 4006 | 2224 | 1456 | 849 | 566 | |
Comparison group with baseline CHF (3) | Proportion | 0.5962 | 0.4514 | 0.3563 | 0.2788 | 0.2360 | 0.1929 |
At risk | 303 | 195 | 118 | 76 | 42 | 27 | |
Comparison group with no baseline CHF (4) | Proportion | 0.5869 | 0.4600 | 0.3319 | 0.2667 | 0.2227 | 0.1926 |
At risk | 6125 | 4133 | 2356 | 1581 | 931 | 623 | |
Clustered P values for between-group comparisons in the high-TG analysis | |||||||
1 vs 2 | 1 vs 3 | 1 vs 4 | 2 vs 3 | 2 vs 4 | 3 vs 4 | ||
0.026 | 0.336 | 0.093 | 0.419 | 0.059 | 0.761 |